GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (OTCPK:INRLF) » Definitions » Cyclically Adjusted PS Ratio

Valneva SE (Valneva SE) Cyclically Adjusted PS Ratio : 2.27 (As of May. 25, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Valneva SE Cyclically Adjusted PS Ratio?

As of today (2024-05-25), Valneva SE's current share price is $4.328. Valneva SE's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $1.91. Valneva SE's Cyclically Adjusted PS Ratio for today is 2.27.

The historical rank and industry rank for Valneva SE's Cyclically Adjusted PS Ratio or its related term are showing as below:

INRLF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.76   Med: 4.14   Max: 23.42
Current: 2.13

During the past years, Valneva SE's highest Cyclically Adjusted PS Ratio was 23.42. The lowest was 1.76. And the median was 4.14.

INRLF's Cyclically Adjusted PS Ratio is ranked better than
71.94% of 506 companies
in the Biotechnology industry
Industry Median: 5.565 vs INRLF: 2.13

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Valneva SE's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.248. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.91 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Valneva SE Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Valneva SE's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Cyclically Adjusted PS Ratio Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.37 7.04 17.61 3.65 2.63

Valneva SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.74 3.76 3.11 2.63 2.00

Competitive Comparison of Valneva SE's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Valneva SE's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Valneva SE's Cyclically Adjusted PS Ratio falls into.



Valneva SE Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Valneva SE's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=4.328/1.91
=2.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valneva SE's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Valneva SE's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.248/119.4700*119.4700
=0.248

Current CPI (Mar. 2024) = 119.4700.

Valneva SE Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.195 100.180 0.233
201409 0.278 99.920 0.332
201412 0.244 99.860 0.292
201503 0.288 100.170 0.343
201506 0.283 100.440 0.337
201509 0.307 99.950 0.367
201512 0.305 100.040 0.364
201603 0.367 100.020 0.438
201606 0.389 100.630 0.462
201609 0.265 100.340 0.316
201612 0.372 100.650 0.442
201703 0.367 101.170 0.433
201706 0.317 101.320 0.374
201709 0.311 101.330 0.367
201712 0.453 101.850 0.531
201803 0.543 102.750 0.631
201806 0.380 103.370 0.439
201809 0.295 103.560 0.340
201812 0.479 103.470 0.553
201903 0.406 103.890 0.467
201906 0.352 104.580 0.402
201909 0.355 104.500 0.406
201912 0.403 104.980 0.459
202003 0.423 104.590 0.483
202006 0.157 104.790 0.179
202009 0.147 104.550 0.168
202012 0.681 104.960 0.775
202103 0.299 105.750 0.338
202106 0.300 106.340 0.337
202109 0.253 106.810 0.283
202112 3.257 107.850 3.608
202203 0.222 110.490 0.240
202206 0.695 112.550 0.738
202209 1.464 112.740 1.551
202212 0.850 114.160 0.890
202303 0.257 116.790 0.263
202306 0.309 117.650 0.314
202309 0.300 118.260 0.303
202312 0.329 118.390 0.332
202403 0.248 119.470 0.248

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Valneva SE  (OTCPK:INRLF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Valneva SE Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Valneva SE's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE (Valneva SE) Business Description

Industry
Traded in Other Exchanges
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.